QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-125-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...

 instil-bio-says-immuneonco-biopharma-presents-preliminary-efficacy-and-safety-data-of-2510-as-monotherapy-in-phase-1-study-of-patients-in-china-with-previously-treated-sq-nsclc-at-2025-wclc

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scoresDifferentiated structure of ‘251...

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-125-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-125-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-125-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.

 jmp-securities-reiterates-market-perform-on-instil-bioto-market-perform

JMP Securities analyst Reni Benjamin reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Market Perform.

 hc-wainwright--co-maintains-buy-on-instil-bio-lowers-price-target-to-105

HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and lowers the price target fro...

 instil-bio-immuneonco-advance-lung-cancer-drug-2510-with-new-trials-in-china-and-us-plans-ahead

Instil Bio, Inc. (NASDAQ:TIL, ", Instil", ))) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, &#...

 instil-bio-q1-adj-eps-132-beats-259-estimate

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(2.59) by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION